19.39
price up icon3.75%   0.70
after-market 시간 외 거래: 19.39
loading
전일 마감가:
$18.69
열려 있는:
$19.06
하루 거래량:
1.31M
Relative Volume:
1.42
시가총액:
$2.18B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-9.0186
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
+12.02%
1개월 성능:
-3.20%
6개월 성능:
+6.13%
1년 성능:
+2.81%
1일 변동 폭
Value
$18.78
$20.08
1주일 범위
Value
$16.95
$20.08
52주 변동 폭
Value
$14.06
$27.29

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name
명칭
Newamsterdam Pharma Company Nv
Name
전화
35 206 2971
Name
주소
GOOIMEER 2-35, NARRDEN
Name
직원
77
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
NAMS's Discussions on Twitter

NAMS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
NAMS
Newamsterdam Pharma Company Nv
19.39 1.94B 14.09M -176.94M -141.24M -2.15
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.27 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.85 114.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.98 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
484.93 63.90B 14.09B 4.50B 2.96B 39.28

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-04 개시 Cantor Fitzgerald Overweight
2024-12-30 개시 H.C. Wainwright Buy
2024-05-15 개시 TD Cowen Buy
2024-03-14 개시 Scotiabank Sector Outperform
2024-01-18 개시 Guggenheim Buy
2024-01-16 개시 Piper Sandler Overweight
2023-10-30 개시 RBC Capital Mkts Outperform
모두보기

Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스

pulisher
Jun 04, 2025

Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target - marketscreener.com

Jun 04, 2025
pulisher
Jun 03, 2025

RBC Capital maintains outperform rating for NewAmsterdam Pharma stock By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

RBC Capital maintains outperform rating for NewAmsterdam Pharma stock - Investing.com India

Jun 03, 2025
pulisher
May 31, 2025

Northern Trust Corp Takes $556,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

May 31, 2025
pulisher
May 30, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Rating Increased to Hold at Wall Street Zen - Defense World

May 30, 2025
pulisher
May 29, 2025

(NAMSW) Proactive Strategies - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Shareholders Will Probably Not Have Any Issues With NewAmsterdam Pharma Company N.V.'s (NASDAQ:NAMS) CEO Compensation - simplywall.st

May 29, 2025
pulisher
May 27, 2025

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - The Manila Times

May 27, 2025
pulisher
May 27, 2025

NewAmsterdam Pharma CEO to Present at William Blair, Jefferies, and Goldman Sachs Healthcare Conferences - Stock Titan

May 27, 2025
pulisher
May 25, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Recommendation of “Buy” by Analysts - Defense World

May 25, 2025
pulisher
May 24, 2025

(NAMS) Technical Pivots with Risk Controls - news.stocktradersdaily.com

May 24, 2025
pulisher
May 23, 2025

NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market - Investing.com Canada

May 23, 2025
pulisher
May 22, 2025

35,657 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by BNP Paribas Financial Markets - Defense World

May 22, 2025
pulisher
May 20, 2025

Financial Contrast: NewAmsterdam Pharma (NAMS) versus Its Rivals - Defense World

May 20, 2025
pulisher
May 19, 2025

(NAMSW) Investment Analysis - news.stocktradersdaily.com

May 19, 2025
pulisher
May 19, 2025

The Manufacturers Life Insurance Company Purchases New Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

May 19, 2025
pulisher
May 15, 2025

Tower Research Capital LLC TRC Sells 6,485 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

May 15, 2025
pulisher
May 14, 2025

Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know - MSN

May 14, 2025
pulisher
May 14, 2025

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

NewAmsterdam Pharma Showcases Non-Statin CVD Pipeline at Major RBC Healthcare Conference - Stock Titan

May 14, 2025
pulisher
May 13, 2025

(NAMS) Proactive Strategies - news.stocktradersdaily.com

May 13, 2025
pulisher
May 13, 2025

Analysts Have Been Trimming Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target After Its Latest Report - simplywall.st

May 13, 2025
pulisher
May 10, 2025

Barclays PLC Buys 9,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

May 10, 2025
pulisher
May 10, 2025

Needham & Company LLC Issues Pessimistic Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World

May 10, 2025
pulisher
May 09, 2025

NewAmsterdam Pharma Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

NewAmsterdam Pharma Q1 Net Loss Narrows, Revenue Rises - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

NewAmsterdam Pharma Company NV reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025
pulisher
May 08, 2025

NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

Ratios Revealed: Decoding NewAmsterdam Pharma Company NV (NAMS)’s Financial Health - DWinneX

May 08, 2025
pulisher
May 08, 2025

Earnings Flash (NAMS) NewAmsterdam Pharma Co. NV Reports Q1 Revenue $2.98M, vs. FactSet Est of $1.6M - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Earnings Flash (NAMS) NewAmsterdam Pharma Co. NV Reports Q1 Revenue $3M, vs. FactSet Est of $1.6M - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

NewAmsterdam Pharma Q1 2025 Financial Results and Corporate Update - TradingView

May 08, 2025
pulisher
May 08, 2025

Envestnet Asset Management Inc. Sells 8,738 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

May 08, 2025
pulisher
May 07, 2025

NewAmsterdam Pharma Announces Late-Breaking Data from - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

NewAmsterdam Pharma (NAMS) Reveals Promising Phase 3 Study Results for Obicetrapib | NAMS Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

NewAmsterdam Pharma Presents Promising Phase 3 Trial Data - TipRanks

May 07, 2025
pulisher
May 07, 2025

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 - marketscreener.com

May 07, 2025
pulisher
May 03, 2025

Trend Tracker for (NAMS) - news.stocktradersdaily.com

May 03, 2025
pulisher
May 03, 2025

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33 - Defense World

May 03, 2025
pulisher
May 02, 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 02, 2025
pulisher
May 02, 2025

NewAmsterdam Pharma Expands Clinical Team with 11 New Hires, Awards $4M in Equity Grants - Stock Titan

May 02, 2025
pulisher
May 01, 2025

Examining NewAmsterdam Pharma Company NV (NAMS) stock is warranted - uspostnews.com

May 01, 2025
pulisher
Apr 30, 2025

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress - GlobeNewswire

Apr 30, 2025
pulisher
Apr 30, 2025

Major Breakthrough: NewAmsterdam Reveals Multiple Phase 3 Trial Results for Novel Heart Drug - Stock Titan

Apr 30, 2025
pulisher
Apr 30, 2025

Geode Capital Management LLC Raises Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

Apr 30, 2025
pulisher
Apr 29, 2025

NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey

Apr 29, 2025
pulisher
Apr 29, 2025

Legal & General Group Plc Acquires 4,556 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

Apr 29, 2025

Newamsterdam Pharma Company Nv (NAMS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.16
price up icon 0.00%
$573.50
price down icon 0.54%
$36.08
price up icon 15.90%
$305.31
price up icon 0.51%
$4.75
price up icon 3.70%
$484.93
price down icon 0.60%
자본화:     |  볼륨(24시간):